Barchart.com's Chart of the Day - Xenon Pharma
Related Stocks
 XENE - Xenon Pharmace Cm Sh
SymLastChgPct
XENE8.47+0.19+2.29%

The Barchart Chart of the Day belongs to Xenon Pharmaceuticals (XENE). I found the biopharmaceutical stock by using Barchart to sort today's Top Stocks to Own list first by the highest Weighted Alpha, then I used the Flipchart featute to review the charts for consistent price appreciation over the past 6 months. Since the Trend spotter signaled a buy on 6/4 the stock gained 94.35%.

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.

XENEBarchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report.

Barchart technical indicators:

  • 100% technical buy signals
  • 387.20+ Weighted Alpha
  • 338.18% gain in the last year
  • Trend Spotter buy signal
  • Above its 20, 50 and 100 day moving averages
  • 6 new highs and up 25.52% in the last month
  • Relative Strength Index 71.71%
  • Technical support level at 10.20
  • Recently traded at 12.10 with a 50 day moving average of 8.84

Fundamental factors:

  • Market Cap $156 million
  • Revenue expected to grow 1295.50% this year but shrink 23.30% next year
  • Earnings estimated to increase 17.00% this year, decrease by 19.70% next year but continue to compound at an annual rate of 57.80% for the next 5 years
  • Wall Street analysts presently have 2 strong buy and 1 buy recommendation in place on the stock